Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
United States of America et al v. Astrazeneca Biopharmaceuticals, Inc. et al
Case Number:
1:14-cv-01718
Court:
Nature of Suit:
Judge:
Firms
Companies
Sectors & Industries:
-
May 15, 2017
26 States Rejoin FCA AstraZeneca Suit Over Seroquel
A New York federal judge on Monday reinstated the False Claims Act claims of 26 states, Washington, D.C., and the city of Chicago in a whistleblower suit accusing AstraZeneca PLC of hiding safety information about antipsychotic drug Seroquel, after the whistleblower acknowledged that she had no authority to voluntarily drop their claims.
-
April 18, 2017
AstraZeneca Can't Shed FCA Suit Over Seroquel 'Scheme'
A New York federal judge on Monday preserved a whistleblower’s False Claims Act suit accusing AstraZeneca PLC of concealing safety information about antipsychotic drug Seroquel, finding plausible allegations of a “complex fraudulent scheme.”
-
August 26, 2016
FCA Attys Clash Over Escobar Test For Implicit Compliance
False Claims Act attorneys are deeply split over a crucial section in the U.S. Supreme Court's Escobar ruling, debating whether its test of implicit statements about regulatory compliance is mandatory and how the test should be applied.
-
August 15, 2016
DOJ, Defense Attys Brawl Over Escobar's FCA Impact
The U.S. Department of Justice and defense attorneys are sharply divided over the U.S. Supreme Court's recent Escobar decision, debating whether it limited False Claims Act liability to situations where the government would have denied payment had it known about misconduct.